Blood Plasma Extender Patents (Class 514/833)
  • Patent number: 8013022
    Abstract: Disclosed is a multi-compartment medical device useful in the storage, processing and extended shelf life of perishable products, especially pharmaceutical, food and biological products. Particular biological materials processed according to the present methods are human blood and blood products (RBCs). Also disclosed are processes for preserving food, pharmaceutical and biological products for long-term storage and extended shelf life employing a process that reduces the hydration level of the material to less than native hydration levels of the specific product. The invention further provides stabilized biological products, such as in the form of glassified beads, prepared using a two-phase system according to the described processes that may be rehydrated and prepared for clinical use, and having essentially no loss of biological and/or pharmacological activity.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: September 6, 2011
    Inventors: Joseph DeAngelo, David Needham, Carroll Jones
  • Patent number: 7309502
    Abstract: The present invention relates to a pharmaceutical composition and the method for the preparation thereof. The composition comprises 1.5˜6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, and the like, and 3˜18% (w/v) of one or more substances selected from hydroxyethylstarch, dextran, carboxymethylstarch, polyvinyl-pyrrolidone, gelatin derivatives, and the like as well as the remainder of conventional injections, as long as sodium chloride is not less than 1.5% (w/v). The pharmaceutical composition of the present invention is used to treat and save the wounded and patients, as well as to treat shock, its advantages include safe and convention use, rapid and good curative effect, long time maintenance, extensive uses and the like.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: December 18, 2007
    Inventor: Chaoying Zhao
  • Patent number: 7101846
    Abstract: Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: September 5, 2006
    Assignee: The Regents of the University of California
    Inventor: Robert M. Winslow
  • Patent number: 7041655
    Abstract: In accordance with the invention there is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The invention also provides a method for preventing the harmful effects of free radicals on cellular membranes and other organelles. The method comprises administering to a subject an effective amount of a composition comprising at least one polysaccharide selected from the group consisting of hydroxyethyl starch and dextran of varying molecular sizes and at least one member of the group consisting of superoxide dismutase, glutathione peroxidase, catalase, hydroxyethyl rutoside, cyclic adenosine monophosphate and vitamin C. The compositions contain the macromolecules in a molecular size and concentration to effectively stabilize the capillary membrane.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: May 9, 2006
    Inventors: Bashir Zikria, Jemal D. Zikria
  • Patent number: 6986905
    Abstract: The present invention relates to a pharmaceutical composition and the method for the preparation thereof, The composition comprises 1.5˜6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, and the like, and 3˜18% (w/v) of one or more substances selected from hydroxyethylstarch, dextran, carboxymethylstarch, polyvinyl-pyrrolidone, gelatin derivatives, and the like as well as the remainder of conventional injections, as long as sodium chloride is not less than 1.5% (w/v). The pharmaceutical composition of the present invention is used to treat and save the wounded and patients, as well as to treat shock, its advantages include safe and convenient use, rapid and good curative effect, long time maintenance, extensive uses and the like.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: January 17, 2006
    Inventor: Chaoying Zhao
  • Patent number: 6599878
    Abstract: The present invention provides superoxygenating compositions that comprise hemoglobin and guanosine 3′:5′-cyclic monophosphate (cyclic GMP) generating compounds, and methods for treatment of diseases or medical conditions which utilize the superoxygenating compositions as biocolloids, i.e. hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids. The cardiac output-increasing compositions comprise a simple mixture of hemoglobin and the cyclic GMP generating compounds or hemoglobin physically or chemically coupled to the cyclic GMP generating compounds. The invention also provides time-controlled superoxygenating compositions of hemoglobin and cyclic GMP generating compounds that would be used for treatment of specific diseases or medical conditions requiring time-dependent use of biocolloids, i.e. hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: July 29, 2003
    Inventor: Michael W. Rooney
  • Patent number: 6562872
    Abstract: An emulsion of perfluoroorganic compounds (PFOC) comprises a rapidly eliminable perfluorocarbon (PFC) and a slowly eliminable perfluorinated cyclic tertiary amine, perfluoro-N-4-(methylcyclohexyl)-piperidine and additionally comprises not less then three rapidly eliminable and three slowly eliminable PFOC admixtures with the critical temperature of dissolution in hexane (CTDH) close to that of main PFOC. The PFOC emulsion is stabilized with a polyoxyethylene-polyoxypropylene copolymer having low viscosity to provide high dynamic oxygen capacity and enhancing oxygen delivery to tissues. To prepare the emulsion the stabilizing agent is heated up to 75° C., all components are saturated with carbon dioxide gas to minimize the reactogenicity in intravessel injection as a means of compensation for mass blood loses, perfusion of organs cut of blood flow, treating air-and fat embolism, obliterating vascular injuries of extremities and preventing toxic injuries caused by various xenobiotics.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: May 13, 2003
    Assignee: Otkrytoe Aktsionernoe Obschestvo Naucho-Proizvodstven-Naya Firma “Perftoran”
    Inventors: Evgeny Iliich Maevsky, Genrikh Romanovich Ivanitsky, Kirill Nikolaevich Makarov, Galina Mikhailovna Kulakova, Vladimir Viktorovich Arkhipov, Viktor Vasilievich Moroz, Ljudmila Nikolaevna Starovoitova, Raisa Yakovlevna Senina, Sergei Jurievich Pushkin, Albina Ivanovna Ivashina
  • Patent number: 6432918
    Abstract: Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: August 13, 2002
    Assignee: The Regents of the University of California
    Inventor: Robert M. Winslow
  • Patent number: 6187744
    Abstract: Methods for time-regulated prophylaxis or treatment of animals or humans for limited circulatory oxygen delivery induced by the inhibitory effects of a plasma-borne hemoglobin-based material on L-arginine→nitric oxide→cGMP pathways in the arteriovenous vasculature. The properties of the invention restore and increase circulatory oxygen delivery by increasing circulatory flow of the blood-hemoglobin-based material through selective activation of L-arginine→nitric oxide→cGMP pathways in the arterial rather than venous vasculature. A method of the invention utilizes oxygen-carrying biocolloid compositions that consist of a hemoglobin-based material and a guanosine 3′:5′-cyclic monophosphate (cGMP) generating entity, for treatment of animals and humans in need thereof for diseases or medical conditions which utilize the biocolloids as hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 13, 2001
    Inventor: Michael W. Rooney
  • Patent number: 6117838
    Abstract: A method of treating a mammal suffering from hypotension by administering intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: September 12, 2000
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 6113919
    Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formulaR.sub.F.sup.1 --W--R.sub.H.sup.1 (I)whereinR.sub.F.sup.1 is a linear, branched or cyclic C.sub.2-14 fluorocarbon group;R.sub.H.sup.1 is a linear, branched or cyclic C.sub.2-18 saturated or unsaturated hydrocarbon group; andW is absent or is a bivalent species chosen from the group consisting of --O--, --S--, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 5, 2000
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jean G. Reiss, Michele Postel, Luis Sole-Violan, Marie-Pierre Krafft, Chantal Cornelus
  • Patent number: 6090779
    Abstract: Therapeutic treatment of septic shock comprises administering to an animal stroma-free hemoglobin, typically at a dose ranging from the least amount effective to increase perfusion, up to a dosage of about 2500 milligrams kilograms per of body weight.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: July 18, 2000
    Assignee: Baxter International, Inc.
    Inventors: Robert J. Przybelski, Kenneth E. Burhop
  • Patent number: 6080397
    Abstract: The present invention relates to compositions for use in medicine, e.g. as infusion or surgical rinse solutions, and to processes for their preparation. The compositions of the invention comprise an aqueous solution of physiologically inert PVP having a weight average molecular weight in the range of from 3,000 to 14,000 daltons.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: June 27, 2000
    Assignee: Ed. Geistlich Sohne AG fur Chemische Industrie
    Inventor: Rolf Wilhelm Pfirrmann
  • Patent number: 6054427
    Abstract: Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: April 25, 2000
    Assignee: The Regents of the University of California
    Inventor: Robert M. Winslow
  • Patent number: 6046161
    Abstract: A method for increasing perfusion in a mammal suffering from cardiogenic shock by administering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: April 4, 2000
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 6022850
    Abstract: A method for increasing perfusion in a mammal suffering from stroke by admninistering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: February 8, 2000
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 6020308
    Abstract: The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as as an adjunct to treatment of inappropriate tissue vascularization disorders.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: February 1, 2000
    Assignees: Duke University, North Carolina State University, Apex Bioscience, Inc.
    Inventors: Mark W. Dewhirst, Robert E. Meyer, Joseph Bonaventura, Joseph DeAngelo
  • Patent number: 5927283
    Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolemic hemodilutions, wounds, diabetic ulcers, chronic leg ulcers, pressure sores, tissue transplants, and sepsis. The compounds are capable of acting on hemoglobin in whole blood.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: July 27, 1999
    Assignee: Virginia Commonwealth University
    Inventors: Donald J. Abraham, Michael Gerber
  • Patent number: 5900477
    Abstract: A method of treating a mammal suffering from hemorrhagic shock or reducing hypotension secondary to hemorrhagic shock in a mammal suffering from hemorrhagic shock by administering intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: May 4, 1999
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 5869539
    Abstract: The present invention involves perfluoro compound emulsions including nitric oxide, their preparation and their use. These emulsions provide a new source of nitric oxide. Such nitric oxide-containing emulsions may be used for the administration of nitric oxide to individuals in need thereof. Individuals in need of nitric oxide administration can include those suffering from hypertension, preeclampsia and a number of other situations where an increased blood flow, for example, is desirable. In addition, given the long use of perfluoro compound emulsions as blood substitutes, the present invention provides a relatively safe mode for administering and distributing nitric oxide-without potential negative side effects such as toxicities due to drug metabolites.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: February 9, 1999
    Assignees: Board of Regents, The University of Texas System, The Texas A&M University System
    Inventors: R. E. Garfield, A. T. Balaban, W. A. Seitz
  • Patent number: 5785950
    Abstract: This invention relates to compositions comprising highly fluorinated, chloro-substituted, non-cyclic organic compounds having 7 to 9 carbon atoms and to processes of making and using them. More particularly, this invention relates to emulsions comprising those highly fluorinated, chloro-substituted organic compounds. This invention also related to emulsion comprising noncyclic perfluorochlorethers having 7 to 10 carbon atoms, preferably 7 to 9 carbon atoms. These novel emulsions have various medical and oxygen transport applications. They are especially useful medically as contrast media, for various biological imaging modalities such as nuclear magnetic resonance, ultrasound, x-ray, computed tomography, .sup.19 F-magnetic resonance imaging, and position emission tomography, as oxygen transport agents or "artificial bloods," in the treatment of heart attack, stroke, and other vascular obstructions, as adjuvants to coronary angioplasty and in cancer radiation treatment and chemotherapy.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: July 28, 1998
    Assignees: HemaGen/PFC, Minnesota Mining & Manufacturing Co.
    Inventors: Robert J. Kaufman, Thomas J. Richard, George G. I. Moore, Richard M. Flynn
  • Patent number: 5776914
    Abstract: Disclosed are compositions and methods for preventing or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use of an anionic oligosaccharide, such as polysulfated cyclodextrin, to achieve the desired reduction in hemolytic active inducing agents.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: July 7, 1998
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Paul B. Weisz, Edward J. Macarak
  • Patent number: 5733894
    Abstract: An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 31, 1998
    Assignee: BioTime, Inc.
    Inventors: Paul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
  • Patent number: 5705521
    Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in radiation oncology applications. The compounds are capable of acting on hemoglobin in whole blood.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 6, 1998
    Assignee: The Center for Innovative Technology
    Inventor: Donald J. Abraham
  • Patent number: 5698536
    Abstract: An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 16, 1997
    Assignee: BioTime, Inc
    Inventors: Paul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
  • Patent number: 5677330
    Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolemic hemodilutions, wounds, diabetic ulcers, chronic leg ulcers, pressure sores, tissue transplants, and sepsis. The compounds are capable of acting on hemoglobin in whole blood.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignees: The Center for Innovative Technology, Allos Therapeutics, Inc.
    Inventors: Donald J. Abraham, Michael Gerber
  • Patent number: 5674913
    Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung or hyperinflated lung syndrome, and instilling a perfluorochemical liquid into the trachea for administration in the alveolar sacs of a lung of the animal. The perfluorochemical is permeable to the ambient gas and resides substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. In another aspect of the invention, the method further includes the step of alleviating the lung disorder without inducing hyperinflated lung syndrome.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: October 7, 1997
    Assignee: Synthetic Blood International, Inc.
    Inventor: Leland C. Clark, Jr.
  • Patent number: 5661182
    Abstract: Drug compounds are used as allosteric modifiers of hemoglobin present in red blood cells. The compounds bind to only a single pair of symmetry related sites in the central water cavity of hemoglobin at the Lys 99.alpha., Arg 141.alpha., and Asn 108 .beta. residues. When one of the drug compounds is bound to hemoglobin, it will join three separate sub-units of the hemoglobin molecule and stabilize the hemoglobin in a lower oxygen affinity state. Because the compounds used in this method are either not bound by serum albumin or only interact to small degrees with serum albumin, the compounds are active in whole blood and in vivo. The process of allosterically modifying hemoglobin towards a low oxygen affinity state in whole blood and in vivo could be used in a wide variety of applications including in treatments for ischemia, heart disease, wound healing, Alzheimer's, depression, schizophrenia, adult respiratory distress syndrome (ARDS), etc.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 26, 1997
    Assignee: Virginia Commonwealth University
    Inventors: Donald J. Abraham, Claude Poyart
  • Patent number: 5661124
    Abstract: The present invention provides blood substitutes comprised of recombinantly produced mutant hemoglobin having an osmolarity greater than 303 milliosmoles per liter and less than 800 milliosmoles per liter. Such hyperosmolar blood substitute additionally comprises a physiologically acceptable molecule less diffusible than dextrose.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: August 26, 1997
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Kiyoshi Nagai
  • Patent number: 5648375
    Abstract: Allosteric hemoglobin modifier compound activity on p50 is potentiated by using the compound in combination with a hydrophobic compound such as an anesthetic.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 15, 1997
    Assignee: Virginia Commonwealth University
    Inventor: Donald J. Abraham
  • Patent number: 5635538
    Abstract: A fluorocarbon emulsion which exhibits reduced pulmonary gas-trapping properties in species-sensitive laboratory animals is disclosed. Additionally, the fluorocarbon component(s) exhibit short organ retention time(s). The emulsion includes an aqueous phase, an emulsifier, and a fluorocarbon (or fluorocarbon composition), having a vapor pressure of less than about 8 torr to reduce pulmonary gas-trapping, and having an organ retention half life of less than about 6 weeks and more preferably less than about 3 to 4 weeks.
    Type: Grant
    Filed: March 16, 1993
    Date of Patent: June 3, 1997
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jeffry G. Weers, Ernest G. Schutt, Timothy J. Pelura, Peter E. Keipert
  • Patent number: 5613944
    Abstract: An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a preadministration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 25, 1997
    Assignee: BioTime, Inc.
    Inventors: Paul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
  • Patent number: 5612310
    Abstract: The present invention is directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone.
    Type: Grant
    Filed: May 24, 1993
    Date of Patent: March 18, 1997
    Assignees: Duke University, North Carolina State University, Apex Bioscience, Inc.
    Inventors: Mark W. Dewhirst, Robert E. Meyer, Joseph Bonaventura, Joseph DeAngelo
  • Patent number: 5574019
    Abstract: The present invention relates to the field of compositions of matter, disclosing compositions of matter which as aqueous solutions, may be used to perfuse a living or non-living subject in need of perfusion. The solutions according to the invention are typified by an aqueous solution comprising a polysaccharide oncotic agent, a physiologically compatible buffer, a simple hexose sugar, dissolved chloride salts of calcium, sodium and magnesium, and a dissolved organic salt of sodium. The solutions according to the invention are effective substitutes for blood. In addition the solution according to the invention may be used to preserve the biological integrity of the organs of a mammalian donor organism as shown by superior anatomical integrity of cryopreserved organs and tissues of subjects perfused with the solution of the invention.
    Type: Grant
    Filed: September 10, 1993
    Date of Patent: November 12, 1996
    Assignee: Biotime, Inc.
    Inventors: Paul E. Segall, Hal Sternberg, Harold D. Waitz
  • Patent number: 5571801
    Abstract: An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: November 5, 1996
    Assignee: Biotime, Inc.
    Inventors: Paul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
  • Patent number: 5567765
    Abstract: This invention relates to physiologically acceptable emulsions of perfluorocarbon ether hydrides having 8 to 12 carbon atoms. These novel emulsions have various medical applications. They are especially useful medically as contrast media for various biological imaging modalities such as nuclear magnetic resonance, .sup.19 F-magnetic resonance imaging, ultrasound, x-ray, and computed tomography, as oxygen transport agents or "artificial bloods" in the treatment of heart attack, stroke, and other vascular obstructions, as adjuvants to coronary angioplasty and in cancer radiation treatment and chemotherapy.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: October 22, 1996
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: George G. I. Moore, Richard M. Flynn, Miguel A. Guerra
  • Patent number: 5525478
    Abstract: The present invention provides a novel one-stage assay which uses soluble thrombomodulin for directly determining the functional status in plasma of the vitamin K-dependent coagulation-inhibiting proteins, protein C and protein S. The method comprises combining a blood plasma test sample and a coagulation-activating substance in a calcium-free solution, then adding soluble thrombomodulin and calcium ions to initiate a coagulation reaction, measuring the time required for the test plasma sample to clot, comparing the measured clot time to that of standard control plasma samples, including protein C- and protein S-deficient plasma controls, and then using the compared clot time values for determining the functional status of protein C and protein S in the individual from whom the test plasma sample was taken. The functional status of the vitamin K-dependent coagulation-inhibiting proteins is used to determine the risk of thrombosis in the host individual.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 11, 1996
    Inventor: John T. Matschiner
  • Patent number: 5502043
    Abstract: The use of a hydroxyethyl starch specification with a molecular weight M.sub.W of 110,000 to 150,000, a substitution level MS of 0.38 to 0.5, a substitution level DS of 0.32 to 0.45, and a C.sub.2 /C.sub.6 ratio from 8 to 20 for improvement of microcirculation in a peripheral arterial circulation disorder, in particular in already existing peripheral arterial occlusive disease in Stage II according to Fontaine. This hydroxyethyl starch specification can be used in suitable concentrations, e.g., as 6 wt.-% or 10 wt.-% solution, whereby these solutions optionally contain conventional adjuvants and additives.
    Type: Grant
    Filed: March 30, 1994
    Date of Patent: March 26, 1996
    Assignee: Fresenius AG
    Inventors: Burghard Weidler, Klaus Sommermeyer, Klaus Henning, Frank Bepperling
  • Patent number: 5498599
    Abstract: Disclosed is a method for increasing the number of platelets in a mammal, which comprises administering to the mammal a platelet number increasing effective amount of an unbound, preferably a soluble, MPL receptor.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: March 12, 1996
    Assignee: AMGEN Inc.
    Inventors: Esther S. Choi, Martha M. Hokom, Pamela Hunt, Janet L. Nichol
  • Patent number: 5470841
    Abstract: A metabolizable blood plasma substitute is described which contains a starch ester with a molecular weight (Mw) of>20000 Daltons and a molar substitution of 0.1 to 1.5 as a colloidal component. The starch ester is for example acetyl starch with a molecular weight (Mw) of 200000 to 230000 Daltons and a molar substitution of 0.3 to 0.5.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: November 28, 1995
    Assignee: Laevosan-Gesellschaft mbH
    Inventors: Harald Forster, Fatima Asskali, Ernst Nitsch
  • Patent number: 5446030
    Abstract: Disclosed are compositions and methods for prevented or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use an anionic oligosaccharide, such as polysulfated cyclodextrin, to achieve the desired reduction in hemolytic active inducing agents.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: August 29, 1995
    Inventors: Paul B. Weisz, Edward J. Macarak
  • Patent number: 5439944
    Abstract: Oil and water emulsions containing alkylphosphoryl choline or alkylglycerophosphoryl choline surfactants are disclosed. The surfactants have the following general structures: ##STR1## In the above general structures, R.sub.1, R.sub.2 or R.sub.3 is alkyl, alkenyl, fluoroalkyl and alkenyl; and PC is the phosphoryl choline. The emulsions are useful as oxygen transport agents, artificial bloods or red blood cell substitutes.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: August 8, 1995
    Assignee: HemaGen/PFC
    Inventors: Robert J. Kaufman, Thomas J. Richard
  • Patent number: 5438041
    Abstract: A process is provided wherein hemoglobin, a fragile material, is formulated into high hemoglobin content water-in-oil-in-water multiple emulsion while maintaining high yields and high oxygen exchange activity. A multiple emulsion of aqueous oxygen carrying material in oil in outer aqueous phase is suitable for provision of oxygen for oxygen transfer processes. A hemoglobin multiple emulsion in physiologically compatible oil in an outer aqueous saline solution is provided in sufficiently small droplet size to provide oxygen flow through blood vessels to desired body tissues or organs thereby providing a blood substitute.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: August 1, 1995
    Assignees: Illinois Institute of Technology, Northfield Laboratories, Inc.
    Inventors: Shuming Zheng, Richard L. Beissinger, Darsh T. Wasan, Lakshman R. Sehgal, Arthur L. Rosen
  • Patent number: 5436232
    Abstract: A pharmaceutical composition is described as well as the use of a starch ester for the production of such a pharmaceutical composition for peritoneal dialysis (CAPD) in particular for continuous ambulatory peritoneal dialysis. Starch esters which are particularly suitable are e.g. acetyl starch with a molecular weight (Mw) of 100000 to 200000 Daltons and a molar substitution of 0.3 to 0.5. Using the compositions according to the invention it is possible to carry out peritoneal dialysis without damaging the peritoneal epithelium. In addition it is not stored in the organs.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: July 25, 1995
    Assignee: Laevosan-Gesellschaft MBH
    Inventors: Harald Forster, Fatima Asskali, Ernst Nitsch
  • Patent number: 5434191
    Abstract: A blood substitute employs combinations of fluoro or perfluorochemicals capable in the presence of emulsifying agents of forming emulsions stable at room temperature and possessing enhanced oxygen carrying capacity; the invention enables preparation of an improved blood substitute, with improved O.sub.2 carrying capacity and stability, as well as lessened anaphylactoid reaction.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: July 18, 1995
    Assignee: International Therapeutics Inc.
    Inventors: Walter B. Dandliker, W. Keith R. Watson, Thomas C. Drees
  • Patent number: 5432191
    Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: July 11, 1995
    Assignee: The Center for Innovative Technology
    Inventors: Donald J. Abraham, Mona Mahran, Ahmed Mehanna, Ramnarayan Randad, Gajanan S. Joshi, Jayashree Panikker
  • Patent number: 5416078
    Abstract: The invention relates to fluid resuscitation of the human or animal body by administration of deferoxamine (DFO) and a water-soluble biopolymer.The DFO and the biopolymer are preferably bonded together.The biopolymer may be a polysaccharide or a protein.The DFO and the biopolymer are preferably formulated as an aqueous solution suitable for oral administration.The fluid resuscitation may be effected for ameliorating systemic oxidant injury occurring during ischemia and subsequent reperfusion.The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived from combustion, hemorrhagic shock and other types of trauma.
    Type: Grant
    Filed: November 25, 1992
    Date of Patent: May 16, 1995
    Assignee: Biomedical Frontiers, Inc.
    Inventors: Bo E. Hedlund, Philip E. Hallaway
  • Patent number: 5314878
    Abstract: A composition for removing or inactivating harmful components including virus from blood or other extracellular liquids comprises a crownether compound substituted on a polysaccharide, preferably dextrane. The composition may be soluble in water, preferably for intraveneous application, or insoluble for extracorporeal application.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: May 24, 1994
    Assignee: A/S af 18. juni 1990
    Inventors: Henry M. Christensen, Hans B. Andreasen
  • Patent number: 5306711
    Abstract: An organ preservative solution containing a low molecular weight dextran in a pharmacologically acceptable storage solution is suitable for storage and preservative of organs for transplantation.
    Type: Grant
    Filed: June 24, 1992
    Date of Patent: April 26, 1994
    Assignee: Georgetown University
    Inventor: Peter Andrews
  • Patent number: RE38459
    Abstract: An injectable physiologically acceptable aqueous phase fluorocarbon emulsion, which has substantially no free fluorocarbon, has an excellent stability is prepared by a process of the invention. Typically, more than about 99.8 wt. % of the fluorocarbon remains in the size range of about 0.2 to 0.4 microns even after being stored at room temperature for one year or more in sealed containers under a non-oxidizing atmosphere. The emulsion is useful in medical applications, for example, coronary angioplasty, cancer therapy, among others.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: March 9, 2004
    Assignee: Thomas Jefferson University
    Inventors: Stuart Raynolds, Robert H. Dettre